Spontaneous Bacterial Peritonitis Clinical Trial
Official title:
Cefotaxime Resistance in Treatment of Spontaneous Bacterial Peritonitis
Spontaneous bacterial peritonitis (SBP) is a serious complication in cirrhotic patients, and the changes in the microbiological characteristics reported in the last years are impacting the choice of antibiotic used in the treatment. Cefotaxime has been the most extensively studied antibiotic for this infection. It is considered to be one of the first choice antibiotics because of low toxicity and excellent efficacy. Treatment of SBP by intravenous cefotaxime should be administered for a minimum 5 days. Antibiotic-resistant microorganisms have been increasingly reported especially to cefotaxime and its effect on the clinical outcome in treating SBP.
Status | Completed |
Enrollment | 254 |
Est. completion date | June 2015 |
Est. primary completion date | May 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - patients with liver cirrhosis and ascites and clinical findings suspicious of ascitic fluid infection Exclusion Criteria: - Patients were excluded if they received antibiotics ten days prior to the hospital admission or there is evidence of secondary bacterial peritonitis, tuberculous peritonitis, malignant ascites or ascites due to other causes e.g. cardiac or renal diseases |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Egypt | Nasser institute | Cairo | Shubra |
Lead Sponsor | Collaborator |
---|---|
Dr Ahmed Ali Elbaz |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Organisms detected with their antibiotics sensitivity | 8 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06026267 -
Efficacy of Conventional Dose Protocol vs Low Dose Protocol Albumin Use in Patients With Cirrhosis and High Risk Spontaneous Bacterial Peritonitis
|
N/A | |
Withdrawn |
NCT02552862 -
Study of the Effect of Adjunctive Vivomixx® in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis (SBP)
|
Phase 3 | |
Completed |
NCT02528097 -
A Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis
|
N/A | |
Completed |
NCT01193426 -
Diagnostic of Spontaneous Bacterial Peritonitis
|
||
Completed |
NCT00359853 -
Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis
|
Phase 4 | |
Active, not recruiting |
NCT04159870 -
Rifaximin Versus Norfloxacin in Spontaneous Bacterial Peritonitis
|
Phase 3 | |
Completed |
NCT04153604 -
Doxycycline for the Prevention of Spontaneous Bacterial Peritonitis
|
||
Completed |
NCT06234046 -
Rifaximin as a Prophylaxis of Spontaneous Bacterial Peritonitis in Comparison With Ciprofloxacin
|
Phase 3 | |
Recruiting |
NCT01598870 -
Diagnosis of Spontaneous Bacterial Peritonitis
|
N/A | |
Recruiting |
NCT00761098 -
Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP)
|
Phase 4 | |
Completed |
NCT05401721 -
Serum Copeptin in Cirrhotic Patients With Spontaneous Bacterial Peritonitis
|
||
Completed |
NCT02468089 -
To Compare the Efficacy of Carbepenem Versus Carbepenem Plus GM-CSF in Difficult To Treat Spontaneous Bacterial Peritonitis
|
N/A | |
Not yet recruiting |
NCT04746937 -
Nitazoxanide in Prevention of Secondary Spontaneous Peritonitis
|
Phase 3 | |
Recruiting |
NCT02759497 -
Evaluation of Serum Amyloid A in Early Diagnosis of Spontaneous Bacterial Peritonitis
|
N/A | |
Completed |
NCT02608658 -
Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites
|
N/A | |
Completed |
NCT03163745 -
Asymptomatic Spontaneous Bacterial Peritonitis in Patients With Decompensated Liver Cirrhosis
|
||
Completed |
NCT04273373 -
Low Dose Albumin Versus Standard Dose Albumin in High Risk Spontaneous Bacterial Peritonitis.
|
N/A | |
Active, not recruiting |
NCT04395365 -
Primary Antibiotic Prophylaxis Using Co-trimoxazole to Prevent Spontaneous Bacterial Peritonitis in Cirrhosis
|
Phase 3 | |
Terminated |
NCT00570960 -
Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis
|
Phase 4 | |
Recruiting |
NCT05422118 -
Ascitic Fluid Calprotectin as an Accurate Diagnostic Marker for Spontaneous Bacterial Peritonitis
|
N/A |